Harmony Biosciences EV/EBIT HRMY

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026: 6.9×
5-year median: 9.8×
Against its 5-year history: 10th; percentile: 0 is its lowest day, 100 its highest
5-year range: 4.4× to 41.9×
Peer median: 11.1×

Harmony Biosciences' EV/EBIT is 6.9× as of Oct 23, 2026.

That is below its 5-year median of 9.8×, lower than on 90% of days in the last 5 years.

Over that time it ranged from 4.4× in Mar 2026 to 41.9× in Nov 2021.

The median for 10 large drugmakers of a similar size is 11.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.9×	4.4×	8.8×
2025	7.5×	4.9×	11.4×
2024	9.8×	7.2×	11.6×
2023	8.6×	6.1×	30.3×
2022	31.1×	20.4×	34.3×
2021	36.3×	30.3×	41.9×

Against its peers

Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.

Company	EV/EBIT
HRMYHarmony Biosciences	6.9×
PBHPrestige Consumer Healthcare	14.5×
ANIPANI Pharmaceuticals	10.5×
NRIXNurix Therapeutics	7.1×
PAHCPhibro Animal Health	11.7×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	7.6×
OGNOrganon	9.5×
OMEROmeros	n/m
LQDALiquidia	21.7×
ARQTArcutis Biotherapeutics	111×
Peer median	11.1×

Where Harmony Biosciences ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Harmony Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.